Eisai在Leqembi家中为老年痴呆早期注射针剂,减少诊所的就诊次数。 Eisai launches at-home Leqembi injection for early Alzheimer’s, reducing clinic visits.

Eisai在美国发动了Leqembi Iqlik, 每周一次向下注射白血球病毒, 作为早期老年痴呆病的维持治疗。 Eisai has launched Leqembi Iqlik, a weekly subcutaneous injection of lecanemab-irmb, in the U.S. as a maintenance treatment for early Alzheimer’s disease. 经过18个月的初期IV治疗后,病人可以转而使用家用自动注射器,这标志着第一个提供这种选择的抗氨基胺疗法。 After 18 months of initial IV therapy, patients may switch to the at-home autoinjector option, marking the first anti-amyloid therapy to offer this choice. 新的选择方案旨在减少诊所访问,改善获得服务的机会,并支持持续治疗以维持福利。 The new option aims to reduce clinic visits, improve access, and support ongoing treatment to maintain benefits. 一个配套方案提供财政和教育支持,包括一个应用程序和注射跟踪。 A companion program provides financial and educational support, including an app and injection tracking.